ARCUS BIOSCIENCES INC (RCUS)

US03969F1093 - Common Stock

15.5  +0.04 (+0.26%)

After market: 15.09 -0.41 (-2.65%)

Fundamental Rating

3

RCUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. The financial health of RCUS is average, but there are quite some concerns on its profitability. RCUS is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCUS had negative earnings in the past year.
In the past year RCUS has reported a negative cash flow from operations.
RCUS had negative earnings in 4 of the past 5 years.
In multiple years RCUS reported negative operating cash flow during the last 5 years.

1.2 Ratios

RCUS's Return On Assets of -21.57% is fine compared to the rest of the industry. RCUS outperforms 75.75% of its industry peers.
The Return On Equity of RCUS (-47.79%) is better than 68.32% of its industry peers.
Industry RankSector Rank
ROA -21.57%
ROE -47.79%
ROIC N/A
ROA(3y)-14.86%
ROA(5y)-20.44%
ROE(3y)-33.6%
ROE(5y)-35.4%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

4

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RCUS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RCUS has more shares outstanding
There is no outstanding debt for RCUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 0.38, we must say that RCUS is in the distress zone and has some risk of bankruptcy.
RCUS's Altman-Z score of 0.38 is fine compared to the rest of the industry. RCUS outperforms 65.49% of its industry peers.
A Debt/Equity ratio of 0.08 indicates that RCUS is not too dependend on debt financing.
RCUS has a Debt to Equity ratio of 0.08. This is in the lower half of the industry: RCUS underperforms 63.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 0.38
ROIC/WACCN/A
WACC11.91%

2.3 Liquidity

RCUS has a Current Ratio of 5.24. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 5.24, RCUS perfoms like the industry average, outperforming 56.11% of the companies in the same industry.
RCUS has a Quick Ratio of 5.24. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS's Quick ratio of 5.24 is in line compared to the rest of the industry. RCUS outperforms 57.52% of its industry peers.
Industry RankSector Rank
Current Ratio 5.24
Quick Ratio 5.24

More info and screens

6

3. Growth

3.1 Past

RCUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.25%, which is quite impressive.
RCUS shows a strong growth in Revenue. In the last year, the Revenue has grown by 119.72%.
Measured over the past years, RCUS shows a very strong growth in Revenue. The Revenue has been growing by 69.35% on average per year.
EPS 1Y (TTM)21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.38%
Revenue 1Y (TTM)119.72%
Revenue growth 3Y14.72%
Revenue growth 5Y69.35%
Sales Q2Q%50%

3.2 Future

Based on estimates for the next years, RCUS will show a small growth in Earnings Per Share. The EPS will grow by 7.92% on average per year.
RCUS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.15% yearly.
EPS Next Y16.46%
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%
EPS Next 5Y7.92%
Revenue Next Year129.3%
Revenue Next 2Y36.26%
Revenue Next 3Y25.97%
Revenue Next 5Y41.15%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCUS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

RCUS's earnings are expected to decrease with -2.75% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (12/20/2024, 8:04:00 PM)

After market: 15.09 -0.41 (-2.65%)

15.5

+0.04 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-19 2025-02-19/amc
Inst Owners58.57%
Inst Owner Change4.12%
Ins Owners7.75%
Ins Owner Change-0.05%
Market Cap1.42B
Analysts81.05
Price Target34.68 (123.74%)
Short Float %14.77%
Short Ratio10.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.35%
Min EPS beat(2)7.78%
Max EPS beat(2)8.92%
EPS beat(4)3
Avg EPS beat(4)27.04%
Min EPS beat(4)-3.39%
Max EPS beat(4)94.85%
EPS beat(8)7
Avg EPS beat(8)19.54%
EPS beat(12)10
Avg EPS beat(12)62.86%
EPS beat(16)10
Avg EPS beat(16)43.48%
Revenue beat(2)2
Avg Revenue beat(2)37.29%
Min Revenue beat(2)25.3%
Max Revenue beat(2)49.28%
Revenue beat(4)4
Avg Revenue beat(4)100.38%
Min Revenue beat(4)7.14%
Max Revenue beat(4)319.8%
Revenue beat(8)6
Avg Revenue beat(8)56.29%
Revenue beat(12)9
Avg Revenue beat(12)106.15%
Revenue beat(16)10
Avg Revenue beat(16)77.36%
PT rev (1m)5.35%
PT rev (3m)-0.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.79%
EPS NY rev (1m)-2.51%
EPS NY rev (3m)-11.43%
Revenue NQ rev (1m)-2.03%
Revenue NQ rev (3m)18.62%
Revenue NY rev (1m)6.89%
Revenue NY rev (3m)-2.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.39
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-3.15
EYN/A
EPS(NY)-4.92
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS2.87
BVpS6.17
TBVpS6.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.57%
ROE -47.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.86%
ROA(5y)-20.44%
ROE(3y)-33.6%
ROE(5y)-35.4%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 110%
Cap/Sales 4.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.24
Quick Ratio 5.24
Altman-Z 0.38
F-Score5
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)362.28%
Cap/Depr(5y)247.92%
Cap/Sales(3y)10.9%
Cap/Sales(5y)9.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.38%
EPS Next Y16.46%
EPS Next 2Y-8.85%
EPS Next 3Y-2.75%
EPS Next 5Y7.92%
Revenue 1Y (TTM)119.72%
Revenue growth 3Y14.72%
Revenue growth 5Y69.35%
Sales Q2Q%50%
Revenue Next Year129.3%
Revenue Next 2Y36.26%
Revenue Next 3Y25.97%
Revenue Next 5Y41.15%
EBIT growth 1Y7.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.25%
EBIT Next 3Y-11.36%
EBIT Next 5YN/A
FCF growth 1Y-139.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.46%
OCF growth 3YN/A
OCF growth 5YN/A